FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082011041> ?p ?o ?g. }

• W3082011041 endingPage "122359" @default.
• W3082011041 startingPage "122359" @default.
• W3082011041 abstract "Glycoengineering and biosimilarity are the key factors for growing, promising and progressive approaches in monoclonal antibodies development. In this study, the physicochemical stability of anti-CD20 rituximab (RTX); originator and biosimilar was compared to its glycoengineered humanized version; obinutuzumab (OBZ). An orthogonal stability-indicating protocol using a set of validated bioanalytical techniques; size exclusion high performance liquid chromatography (SE-HPLC), reversed phase liquid chromatography (RP-HPLC), quantitative gel electrophoresis by TapeStation, receptor binding assay and dynamic light scattering (DLS) was used to investigate the effect of different stress factors on the pattern and kinetics of degradation. SE-HPLC results supported with spectral purity showed similar degradation extent with a different pattern of degradation between RTX and OBZ. A lower tendency to form degraded fragments and a relatively higher favorability for degradation through aggregate formation has been revealed in case of OBZ. Results were in agreement with those of DLS and receptor binding assay which showed specificity to the intact antibodies in the presence of their degradation products. Furthermore, results were additionally confirmed through denaturing quantitative gel electrophoresis which suggested reducible covalent bonds as the mechanism for aggregates formation. RP-HPLC results showed two oxidized forms via excessive oxidation of RTX and OBZ with nearly the same degradation percent. Comparability data of RTX and OBZ using the applied methodologies showed that although glycoengineering; carried out to enhance the therapeutic and biological activity of OBZ altered the pattern of degradation but did not significantly affect the overall stability. Results showed also consistent stability profile between the biosimilar and its originator RTX products." @default.
• W3082011041 created "2020-09-08" @default.
• W3082011041 creator A5018251901 @default.
• W3082011041 creator A5048818284 @default.
• W3082011041 creator A5058244933 @default.
• W3082011041 creator A5075561331 @default.
• W3082011041 creator A5078633938 @default.
• W3082011041 date "2020-11-01" @default.
• W3082011041 modified "2023-10-01" @default.
• W3082011041 title "Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering" @default.
• W3082011041 cites W1532698890 @default.
• W3082011041 cites W1629918075 @default.
• W3082011041 cites W1966573315 @default.
• W3082011041 cites W1969824500 @default.
• W3082011041 cites W1970772838 @default.
• W3082011041 cites W1971970118 @default.
• W3082011041 cites W1981000246 @default.
• W3082011041 cites W1987697390 @default.
• W3082011041 cites W1987895902 @default.
• W3082011041 cites W1988123624 @default.
• W3082011041 cites W2002149424 @default.
• W3082011041 cites W2006980325 @default.
• W3082011041 cites W2009155525 @default.
• W3082011041 cites W2014262451 @default.
• W3082011041 cites W2023985105 @default.
• W3082011041 cites W2036250776 @default.
• W3082011041 cites W2036721571 @default.
• W3082011041 cites W2038017739 @default.
• W3082011041 cites W2040942735 @default.
• W3082011041 cites W2042725832 @default.
• W3082011041 cites W2046128607 @default.
• W3082011041 cites W2048814278 @default.
• W3082011041 cites W2049153191 @default.
• W3082011041 cites W2050513711 @default.
• W3082011041 cites W2058718200 @default.
• W3082011041 cites W2061932771 @default.
• W3082011041 cites W2066357502 @default.
• W3082011041 cites W2068817764 @default.
• W3082011041 cites W2076856328 @default.
• W3082011041 cites W2083982805 @default.
• W3082011041 cites W2086286894 @default.
• W3082011041 cites W2087066457 @default.
• W3082011041 cites W2131909425 @default.
• W3082011041 cites W2135802989 @default.
• W3082011041 cites W2163450464 @default.
• W3082011041 cites W2166126901 @default.
• W3082011041 cites W2306423776 @default.
• W3082011041 cites W2322176051 @default.
• W3082011041 cites W2519207973 @default.
• W3082011041 cites W2563976031 @default.
• W3082011041 cites W2580497094 @default.
• W3082011041 cites W2615381962 @default.
• W3082011041 cites W2617346366 @default.
• W3082011041 cites W2748244654 @default.
• W3082011041 cites W2748410878 @default.
• W3082011041 cites W2766482924 @default.
• W3082011041 cites W2771153738 @default.
• W3082011041 cites W2775810734 @default.
• W3082011041 cites W2790763558 @default.
• W3082011041 cites W2801354368 @default.
• W3082011041 cites W2806838331 @default.
• W3082011041 cites W2946059626 @default.
• W3082011041 cites W903244044 @default.
• W3082011041 doi "https://doi.org/10.1016/j.jchromb.2020.122359" @default.
• W3082011041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32920338" @default.
• W3082011041 hasPublicationYear "2020" @default.
• W3082011041 type Work @default.
• W3082011041 sameAs 3082011041 @default.
• W3082011041 citedByCount "2" @default.
• W3082011041 countsByYear W30820110412022 @default.
• W3082011041 crossrefType "journal-article" @default.
• W3082011041 hasAuthorship W3082011041A5018251901 @default.
• W3082011041 hasAuthorship W3082011041A5048818284 @default.
• W3082011041 hasAuthorship W3082011041A5058244933 @default.
• W3082011041 hasAuthorship W3082011041A5075561331 @default.
• W3082011041 hasAuthorship W3082011041A5078633938 @default.
• W3082011041 hasConcept C114614502 @default.
• W3082011041 hasConcept C159654299 @default.
• W3082011041 hasConcept C185592680 @default.
• W3082011041 hasConcept C197947376 @default.
• W3082011041 hasConcept C203014093 @default.
• W3082011041 hasConcept C2777607594 @default.
• W3082011041 hasConcept C2780653079 @default.
• W3082011041 hasConcept C33923547 @default.
• W3082011041 hasConcept C43617362 @default.
• W3082011041 hasConcept C542903549 @default.
• W3082011041 hasConcept C71924100 @default.
• W3082011041 hasConceptScore W3082011041C114614502 @default.
• W3082011041 hasConceptScore W3082011041C159654299 @default.
• W3082011041 hasConceptScore W3082011041C185592680 @default.
• W3082011041 hasConceptScore W3082011041C197947376 @default.
• W3082011041 hasConceptScore W3082011041C203014093 @default.
• W3082011041 hasConceptScore W3082011041C2777607594 @default.
• W3082011041 hasConceptScore W3082011041C2780653079 @default.
• W3082011041 hasConceptScore W3082011041C33923547 @default.
• W3082011041 hasConceptScore W3082011041C43617362 @default.
• W3082011041 hasConceptScore W3082011041C542903549 @default.
• W3082011041 hasConceptScore W3082011041C71924100 @default.

• next